A stylized globe graphic, with the EU area emphasized
ISIDORe project home / Services / SUSPENDED: Support for Diagnostic & Therapeutic Development

SUPPORT FOR DIAGNOSTIC & THERAPEUTIC DEVELOPMENT

The best of chemical biology for advancing your prevention and intervention tools

SUPPORT FOR THE DEVELOPMENT OF DIAGNOSTICS

Provided to you by the Biomedical Research Foundation, Academy of Athens (BRFAA), the Joanneum Research (JR), and Joint Research Center of European Commission (JRC) in collaboration with EU-OPENSCREEN

Due to the high demand in EU-OPENSCREEN services to support Diagnostic and Therapeutic Development, there is insufficient EC funding to provide you with our services at this time. Feel free to submit a pre-application to enter your research proposal into our list of potential future projects. They will be considered in received order, should additional funding become available in the future. Thank you very much for your understanding.

Contact
EU-OPENSCREEN scientific-projects
scientific-projects@eu-openscreen.eu

Charlotte Wit
charlotte.wit@eu-openscreen.eu

All the services listed below are available for access at BSL-1 or BSL-2 regardless of the call for proposals & research topic that you select in your pre-application form:

  • Characterization of in-vitro diagnostic devices and sensing platforms
    Electron microscopy (SEM-EDX, TEM-EDX); Surface analysis (XPS, TOF-SIMS); Raman Microscope; Array scanner
  • Assay development (molecular and biochemical) and integration to IVD devices
    Customization of existing assays to be integrated into LoCs, biosensors and microfluidics-based devices
  • Testing of developed and optimized assays, biosensors, LoCs and microfluidics-based devices with well-characterized samples
    Extensive biobank of blood & nasopharyngeal samples from patients infected with various viral and bacterial pathogens.
  • Surface functionalization
    Development of surface modification techniques towards biomolecule immobilization and biosensor fabrication or tailoring of surface properties (antifouling, surface energy etc.)
  • Lab-on-a-Chip molecular diagnostics, multiplexed pathogen detection, variant discrimination
  • Lab-on-a-chip design
    Simulation-based fluidics design for existing assays
  • Lab-on-a-chip implementation
    Implementation and adaptation of existing assays into foil-based lab-on-chip
  • Lab-on-a-chip demonstrator
    Foil-based lab-on-chip demonstrator device development for existing assays
  • Matrix customized methods (e.g., non-human samples) and multiplexed pathogen detection
    Development/application of rapid, low cost, high throughput molecular methods for population screening

VECTOR MONITORING

Provided to you by INFRAVEC

Contact
TNA Manager
TNAManager@infravec2.eu

Personalized training in the development and application of molecular diagnostics for vector monitoring
Personalized (1-2 people) laboratory training in state-of-the art molecular biology laboratories to develop and apply molecular diagnostics relevant for modern vector monitoring.

Once you have submitted the ISIDORe pre-application below, please complete the Full application for access to this Personalized Training.
Access to the personnal training application

SUPPORT FOR THE DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS

Provided to you by: EU-OPENSCREEN, EU-OPENSCREEN Partners, ERINHA & EMBRC

Due to the high demand in EU-OPENSCREEN services to support Diagnostic and Therapeutic Development, there is insufficient EC funding to provide you with our services at this time. Feel free to submit a pre-application to enter your research proposal into our list of potential future projects. They will be considered in received order, should additional funding become available in the future. Thank you very much for your understanding.

Contacts
EU-OPENSCREEN scientific-projects
scientific-projects@eu-openscreen.eu

Charlotte Wit
charlotte.wit@eu-openscreen.eu

All the services listed below are available for access regardless of the call for proposals & research topic that you select in your pre-application form. The maximum biosafety level of containment for the performance of the experiments is indicated in the description of the services. For confirming the feasibility of your request, please contact us.

Small molecule libraries – provided ONLY in combination with high throughput screening (HTS) services offered below

  • Repurposing Library
    Preparation of assay-ready plates with drug repurposing libraries containing approved and clinical trial compounds
  • European Chemical Biology Library (ECBL)
    Preparation of assay-ready plates with 100.000 small molecules containing approx. 2464 bioactives
  • EU-OPENSCREEN Fragment Library
    Preparation of plates with approx. 1000 fragments including 88 minifrags
  • EU-OPENSCREEN Bioactives
    Preparation of plates with 2464 bioactives

Assay development, high throughput screening and hit profiling services for identification of active small molecule and host-targeting agents

  • Assay development
    Assay design and development in a broad range of readouts including phenotypic assays in BSL2-BSL3 facilities (bacterial growth inhibition and viral infection inhibition, cell-based HCS, host cell response), and BSL1 in-vitro target-based assays with specific bacterial, viral and human targets
  • Biochemical and enzymatic target-based high-throughput screening
    High-throughput screening using BSL1 in-vitro target-based assays with specific bacterial, viral and human targets. The assay needs to be HTS-compatible with demonstrated performance in 384-well format. The service includes assay transfer, HTS and hit validation
    Do not forget to request library if necessary.
  • Cell-based high-throughput screening
    Cell-based screen including phenotypic, and target-based that can be run in both, human and bacterial, cells in BSL2 facilities. The assay needs to be HTS-compatible with demonstrated performance in 384-well format. The service includes assay transfer, HTS and hit validation
    Do not forget to request library if necessary
  • Low- and medium-throughput screening in BSL3 facilities
    Cell-based screen including phenotypic, and target-based that can be run in human cells and pathogen infection models in BSL3 facilities. The service includes assay transfer, screening and hit validation
  • Fragment screening
    Includes assay development, screening and hit validation
  • Hit validation and profiling
    Disease-relevant models, ADMET, ROS‑tox and others

ISIDORe Services in action

The blood-brain barrier is dysregulated in COVId-19 and serves as a CNS entry route for SARS-CoV-2 doi.org/10.1016/j.stemcr.2021.12.011

Characterization of ACE Inhibitors and AT1R Antagonists with Regard to Their Effect on ACE2 Expression and Infection with SARS-CoV-2 Using a Caco-2 Cell Model
doi.org/10.3390/life11080810

X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease
doi: 10.1126/science.abf7945

Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen
doi.org/10.1021/acsptsci.0c00216

A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection
doi.org/10.1038/s41597-021-00848-4

EVALUATION OF THE SELECTIVE ANTIVIRAL ACTIVITY OF AGENTS IN VIRUS-CELL-BASED ASSAYS

provided by ERINHA

Contact
Audrey Richard
audrey.richard@erinha.eu

High-throughput, BSL-3 / BSL-3+.

Medicinal chemistry support

  • Drug design & evaluation in silico
  • Hit-to-lead development following HTS of small molecules
  • Fragment-to-lead development fragment screening
  • Optimization of potency, selectivity and in vitro/in vivo ADMET properties of small molecule drug candidates
  • Design and synthesis of target degraders (PROTACs, RIBOTACs)

Natural compound libraries

provided by EMBRC

Contact
Davide Di Cioccio
davide.dicioccio@embrc.eu

  • Natural compound libraries (500 compounds) obtained from various marine organisms (bacteria, fungi, sponges)
  • >14000 samples (crude extracts and fractions of pre-fractionated extracts) from marine micro-organisms (i.e., fungi, yeast, bacteria, algae) collected during the EU project PharmaSea. Most samples are stored as 10 mg/mL stocks (DMSO), others at different concentrations or solvent (percentage) or as dried stock.

SUPPORT FOR THE DEVELOPMENT OF ANTIBODY THERAPEUTICS

Provided to you by: EU-OPENSCREEN, EU-OPENSCREEN Partners & ERINHA

Due to the high demand in EU-OPENSCREEN services to support Diagnostic and Therapeutic Development, there is insufficient EC funding to provide you with our services at this time. Feel free to submit a pre-application to enter your research proposal into our list of potential future projects. They will be considered in received order, should additional funding become available in the future. Thank you very much for your understanding.

Contacts
EU-OPENSCREEN scientific-projects
scientific-projects@eu-openscreen.eu

Charlotte Wit
charlotte.wit@eu-openscreen.eu

All the services listed below are available for access regardless of the call for proposals & research topic that you select in your pre-application form. Services using replication-competent pathogens are indicated in the descriptions below along with the biosafety level. When applicable, fragments of pathogens are used (e.g., antibody discovery). For confirming the feasibility of your request, please contact us.

Library preparation

  • VHH library preparation
    Preparation of VHH libraries in phagmid vectors including pSEX81 and pMES4. Libraries from naive or immunized alpaca of very high efficiency.

Nanobody, antibody & antigen identification / engineering

  • Nanobody identification
    The service covers:
  • Protein overexpression in E. coli system (vector provided by applicant)
    • Protein purification and verification by mass spectrometry
    • Phage-display nanobody (VHH) library screen
    • Verification of positive clones by ELISA test
    • Nanobody sequence identification
    • Training
  • Antibody discovery and selection from B cells
    Identification of antibodies from plasma of convalescent patients by B-cell cloning
  • Antigen or antibody design and engineering
    Design and engineering of antibody with specific functions and suitable formats (IgG, Fab, single chain antibodies); engineering for increased stability, solubility, modulation of complement engagement, multi-specific constructs

Antibody and/or antigen production and characterization

  • Antigen and/or antibody production, purification and characterization
    Antibody and/or antigen production and purification, quality control of the samples, biophysical characterization (binding affinity, functionality, epitope mapping), in vitro neutralization assays
  • 3D structural models
    3D structural analysis of antibodies, antigens and antibody-antigen complexes with experimentally guided computational simulations
  • Physico-chemical measurements of quality attributes
    Structure, stability, aggregation (digital electrophoresis, DLS, CD, AUC, Multi Detector-AF4, SPR)
  • Assessment of endotoxin contamination
    LAL tests

Evaluation of the selective antiviral activity of antibodies in virus-cell-based assays

provided by ERINHA

Contact
Audrey Richard
audrey.richard@erinha.eu

High-throughput, BSL-3 / BSL-3+.

3D structural models

3D structural analysis of antibodies, antigens and antibody-antigen complexes with experimentally guided computational simulations

VECTOR RESEARCH: HIGH-THROUGHPUT SCREENING SERVICES

provided to you by INFRAVEC

Contact
TNAManager@infravec2.eu

  • Anopheles barcoded screen in vivo
  • Standard Membrane Feeding Assay (SMFA) of live mosquitoes